Roche sues Biocon and Mylan over biosimilar version of Herceptin in India
7th March, 2014 - 12:31 pm
Categories:
IP Practice in India
IPAB Decisions
News & Updates
Patents
0 Comments
Trastuzumab/Herceptin has been amidst several controversaries off lately and this time it is regarding a biosimilar which has jointly been manufactured by Biocon and Mylan. Background Roche’s breast cancer drug Herceptin sold under the brand names HERCEPTIN, HERCLONTM and BICELTIS is a biological drug used primarily for the treatment for human epidermal growth factor receptor … Continue reading Roche sues Biocon and Mylan over biosimilar version of Herceptin in India
Read more »Applicability of the principle “Proof of the right” to Conventional application
29th January, 2014 - 5:31 am
Categories:
IP Practice in India
IPAB Decisions
News & Updates
Patents
0 Comments
This article relates to a recent judgment of IPAB in the case “NTT DoCoMo Inc. Vs The Controller of Patents and Designs” for a patent application No. 794/CHE/2006 which was refused to proceed further by the Indian patent office. Brief summary of the case In summary, the application relates to “TRANSMISSION RATE CONTROL METHOD AND … Continue reading Applicability of the principle “Proof of the right” to Conventional application
Read more »GSK’s patent on lapatinib ditosylate revoked by IPAB
8th August, 2013 - 9:36 am
Categories:
IP Practice in India
Pharma/Biotech Patent Litigations
0 Comments
GSK’s granted patent IN221171 (‘171) on lapatinib ditosylate (marketed as Tykerb), a tyrosine kinase inhibitor for treating breast cancer, was revoked by IPAB by its order of 27th July, 2013. A revocation application was filed by Fresenius Kabi Oncology Limited. The patent is revoked on ground of non-compliance with S.3d alone on basis of no … Continue reading GSK’s patent on lapatinib ditosylate revoked by IPAB
Read more »The Madrid System for the International Registration of Marks (Madrid System)
The “Madrid System” is a centrally administered system of obtaining a bundle of trademark registrations in different jurisdictions. It is governed by two treaties, the Madrid Agreement and the Madrid Protocol, and is administered by the International Bureau of WIPO in Geneva, Switzerland. Madrid System permits the filing, registration and maintenance of trade mark rights … Continue reading The Madrid System for the International Registration of Marks (Madrid System)
Read more »Monsanto’s Patent on Method of Producing Transgenic Plants refused by IPAB
Monsanto’s Indian patent application 2407/DEL/NP/2006 on transgenic plants with heat/salt/draught tolerant plants is rejected by IPAB. The subject patent application is directed to a method of producing a draught/stress/heat/salt/drug tolerant transgenic plants by inserting a recombinant DNA molecule that expresses a cold shock protein CspA or CspB. The subject patent application was rejected by the … Continue reading Monsanto’s Patent on Method of Producing Transgenic Plants refused by IPAB
Read more »India Joins Madrid Protocol
India became signatory to the Madrid Protocol for International Registration of Marks at the World Intellectual Property Organisation (WIPO) on 8th April 2013. Now, Indian applications can register their Trade Marks in as many as 89 countries through a single application. India is the 14th G-20 economy to accede to the protocol. The treaty will … Continue reading India Joins Madrid Protocol
Read more »Opposition against Monsanto’s European Patent on a virus resistant Melon Plant variety
21st February, 2012 - 4:44 pm
Categories:
IP Practice in India
Pharma/Biotech Patent Litigations
0 Comments
Dr. Vandana Shiva, an Indian Environmental Activist has lent her support to “No Patent on Seeds”, a European coalition, in opposing the European Patent EP1962578 granted to Monsanto in May 2011. The Patent claims a melon variety having resistance to Curcurbit Yellow Stunting Disorder Virus (CYSDV) with virus resistance traits taken from melon varieties found … Continue reading Opposition against Monsanto’s European Patent on a virus resistant Melon Plant variety
Read more »Practice Pointer Series: Brief on Patenting Diagnostic Methods in India
Patenting of medical methods is prohibited in India according to Section 3 (i) of the Indian Patent Act, which states that “any process for the medicinal, surgical, curative, prophylactic [diagnostic therapeutic] or other treatment of human beings or any process for a similar treatment of animals to render them free of disease or to increase … Continue reading Practice Pointer Series: Brief on Patenting Diagnostic Methods in India
Read more »“Should there be a single global institution with exclusive competence to conduct international negotiations on intellectual property rights? If so, should this be WIPO, the WTO or some other body?”
INTRODUCTION For harmonising IPRs at international level, providing common forum for negotiation and resolving disputes between members state we need single global institution. Earlier WIPO was the main forum for international negotiations of IPR and then WTO implemented TRIPs agreement came and become main forum replacing WIPO. Both these institutions working method is different, and … Continue reading “Should there be a single global institution with exclusive competence to conduct international negotiations on intellectual property rights? If so, should this be WIPO, the WTO or some other body?”
Read more »Inventors, All Technologies Aren’t Worth Billions
31st July, 2011 - 6:23 pm
Categories:
Hi Tech Patent Commercialisation
Patent Commercialisation
Pharma- biotech- Patent Commercialisation
0 Comments
Working in the IP/Technology Commercialization and Out-Licensing domain makes you assess and evaluate commercial viability of numerous IP backed inventions across technology domains. Apart from learning about and assessing new technologies, we also tend to learn quite of lot about Inventors mindset, specifically about their perspective of their own inventions. This article relates to our … Continue reading Inventors, All Technologies Aren’t Worth Billions
Read more »